What is the best treatment for erectile dysfunction in men?

There is no single “best” treatment for erectile dysfunction (ED) in men, as the optimal approach depends entirely on the underlying cause, overall health status, individual preferences, and response to therapy. Evidence-based management begins with a thorough clinical evaluation—including medical history, physical examination, and targeted investigations (e.g., fasting glucose, lipid profile, testosterone level, and assessment for cardiovascular risk factors)—to identify reversible contributors such as diabetes, hypertension, hypogonadism, depression, medication side effects, or lifestyle factors like smoking, excessive alcohol use, sedentary behavior, or obesity.

First-line pharmacologic therapy typically includes oral phosphodiesterase type 5 (PDE5) inhibitors—such as sildenafil, tadalafil, vardenafil, or avanafil—which enhance nitric oxide–mediated vasodilation in the corpora cavernosa during sexual stimulation. These agents are effective in approximately 70% of men with mild-to-moderate ED and have well-established safety profiles when contraindications (e.g., concurrent nitrates, severe cardiac instability) are excluded.

Non-pharmacologic interventions are equally critical: structured lifestyle modification—including regular aerobic exercise, weight loss if overweight, smoking cessation, and moderation of alcohol intake—has been shown to improve endothelial function and may restore spontaneous erections in some patients. Psychological counseling or sex therapy is indicated when performance anxiety, relationship stress, or depressive symptoms contribute significantly to ED.

For men who do not respond to or cannot tolerate PDE5 inhibitors, second-line options include intracavernosal injection therapy (e.g., alprostadil), intraurethral alprostadil, vacuum erection devices, or low-intensity shockwave therapy (though the latter remains investigational and is not yet universally endorsed by major urologic guidelines). Penile prosthesis implantation is a highly effective, definitive surgical option reserved for refractory cases after comprehensive conservative management has failed.

Importantly, ED should never be viewed in isolation—it is often an early marker of systemic vascular disease. Therefore, appropriate cardiovascular risk assessment and long-term follow-up are essential components of care. A personalized, multidisciplinary strategy—coordinated between primary care, urology, endocrinology, cardiology, and mental health professionals when needed—offers the most effective and sustainable outcomes.